Results 161 to 170 of about 196,945 (261)

Toward personalized healthcare: Advances in two‐dimensional nanomaterial‐based flexible electrochemical sensors for physiological monitoring

BMEMat, EarlyView.
This review provides an overview of the properties, composites and application of two‐dimensional (2D) nanomaterials for wearable electrochemical biosensors. Also, the challenges and future prospects of utilizing 2D nanomaterials in wearable electrochemical biosensor applications are discussed.
Kou Zhang, Lu Han, He‐Qing Cai, Xin‐Yu Xue, Yi‐Fei Song, Wu‐Lin Xin, Ying‐Ze Wang, Peng Liu, Juan Liu   +8 more
wiley   +1 more source

Lithocholic Acid Restores Gut Microbiota and Bile Acid Homeostasis to Improve Type 2 Diabetes. [PDF]

Nutrients
Ge H, Guo M, Chen X, Chen L, Yang X, Ge D, Guo L, Luo Y, Ge G, Zhang L, Wang R.   +10 more
europepmc   +1 more source

Vacancy defect‐induced electron homing breaks phosphodiester bonds for RNA depletion‐driven cancer therapy

BMEMat, EarlyView.
Illustration of 5% S‐vacancy Bi2S3 mediated phosphodiester bonds cleavage in RNA of hepatocellular carcinoma cells, which suppressing ERI3 expression, inhibiting cell proliferation and promoting apoptosis. Abstract Genome‐wide hypertranscription is a hallmark of malignant progression.
Chuncheng Yang, Zehao Shen, Guangming Xiang, Zhe Liu, Huaxin Liu, Jiabei Li, Ao Wang, Yelin Wu, Peiran Zhao, Xingwu Jiang, Jinghan Wang, Xiaoqing Jiang, Wenbo Bu   +12 more
wiley   +1 more source

The Microbial Bile Acid Metabolite 3-Oxo-LCA Inhibits Colorectal Cancer Progression. [PDF]

Cancer Res
Sun F, Wang K, Dong X, Secaira-Morocho H, Hui A, Cai C, Sze JJ, Low B, Udgata S, Pasch CA, Huan T, Deming DA, Zhu Q, Jiang J, Fu T.   +14 more
europepmc   +1 more source

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

BMEMat, EarlyView.
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng, Xiaomin Luo, Peng Zhang, Chen Yang, Yuniel Ma, Xinhua Liu   +5 more
wiley   +1 more source

Plasma Bile Acid Profiling Reveals Novel Early Diagnostic Biomarkers for Pediatric Sepsis. [PDF]

J Inflamm Res
Zhang L, Liu J, Chen Y, Lu X, Li K, Li W, Li N, Li F, Wang Y, He D, Sun Z, Guo L, Zhang Q.   +12 more
europepmc   +1 more source

Beyond mammals: the evolution of chewing and other forms of oropharyngeal food processing in vertebrates

Biological Reviews, EarlyView.
ABSTRACT Oropharyngeal food processing exhibits a remarkable diversity among vertebrates, reflecting the evolution of specialised ‘processing centres’ associated with the mandibular, hyoid, and branchial arches. Although studies have detailed various food‐processing strategies and mechanisms across vertebrates, a coherent and comprehensive terminology ...
Daniel Schwarz, Maja Mielke, Stephan Handschuh, Anthony Herrel, Patrick Lemell, Léa Da Cunha, Nicolai Konow   +6 more
wiley   +1 more source

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska, David S. Gottlieb, Kenneth S. Kornman   +2 more
wiley   +1 more source

Integrating bile acid metabolism into precision nutrition strategies for improved swine performance. [PDF]

Anim Nutr
Li S, He Y, Shaoyong W, Wang Y, Jin M.
europepmc   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

Clinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen, Jeffrey L. Woodhead, Brett A. Howell, Lisl K. M. Shoda, Dolly A. Parasrampuria, Jiayin Huang, Megumi Iwai, Faith D. Ottery, Xuegong Wang, Marci English, Kentaro Miyazaki, Paul B. Watkins   +11 more
wiley   +1 more source